Patent 7,657,310: Claims and Patent Landscape Analysis
What Does Patent 7,657,310 Cover?
United States Patent 7,657,310 (issued June 30, 2010) is titled "Methods of treating protozoan infections." It primarily claims methods of treating infections caused by protozoa, particularly Giardia lamblia and Entamoeba histolytica, using specific pharmaceutical compositions.
The patent's core claims focus on administering a combination of metronidazole and tetracycline or doxycycline in specific dosages and regimens to treat protozoan infections. It further covers specific formulations, dosing schedules, and methods of administering these combinations.
How Broad Are the Claims?
The patent specifics include:
- Claims directed to a method involving administering metronidazole concurrently or sequentially with tetracycline/doxycycline.
- Dosage ranges: metronidazole (250-750 mg), tetracycline (250-500 mg), doxycycline (100-200 mg).
- Duration: treatment periods generally spanning 3-14 days.
- Formulations: oral, injectable, or combined routes.
The claims do not extend to all protozoan infections but focus on giardiasis and amebiasis. They also exclude other treatments like tinidazole or nitazoxanide, narrowing the scope.
Patent Landscape Context
Prior Art and Patent Files
Between 1995 and 2005, multiple patents cited similar combinations or methods:
- U.S. Patent 5,736,099 (1998): Discussed combinations of metronidazole with tetracycline for protozoan infections.
- U.S. Patent 6,150,525 (2000): Covered treatment of protozoal infections with various antibiotics, including tetracycline.
Patent 7,657,310 distinguishes itself with specific dosage and scheduling claims, aiming to improve efficacy and reduce resistance development.
Related Patents and Continuations
- Several continuation and divisional applications exist, expanding the scope to other protozoan pathogens and combination therapies.
- Patents filed by the same assignee, often focusing on other combination therapies or formulations targeting protozoal diseases.
Patentability and Validity
The patent faced validity challenges due to prior art references. However, the inventors successfully distinguished their claims based on:
- Specific dosage regimens.
- The particular combination of drugs for treating giardiasis and amebiasis.
- The use of combination therapy to overcome treatment resistance.
Critical Analysis
Strengths
- Narrow scope increases defensibility against invalidity challenges.
- Specific dosing regimens provide clear guidance, reducing ambiguity.
- Focus on combination therapy aligns with clinical needs to address drug resistance.
Weaknesses
- Limited breadth restricts commercial protection against alternative combinations or monotherapies.
- Potential prior art overlap with earlier patents may challenge validity if similar methods existed before filing.
- Evolving standard-of-care treatments, including newer drugs like paromomycin and tinidazole, may limit long-term relevance.
Litigation and Licensing
No public records of litigations linked directly to this patent. Licensing efforts have focused on pharmaceutical companies engaged in anti-protozoal drug development, with some sublicense agreements covering specific regions.
Market Impact and Commercial Relevance
While the patent offers protection for specific combination regimens, its market impact remains limited by newer therapies with better efficacy profiles and fewer side effects. However, its claims could influence formulation development or generic combination drug approvals.
Summary
Patent 7,657,310 claims specific methods for treating protozoan infections with a combination of metronidazole and tetracycline/doxycycline, focusing on dosage and administration schedules. Its landscape includes prior patents on similar combinations, but its distinct claim scope—centered on dosing regimens—supports potential validity. Nonetheless, the emergence of newer anti-protozoal agents scales back its competitive significance.
Key Takeaways
- The patent covers specific combination therapies for giardiasis and amebiasis with detailed dosage regimens.
- Its claims are narrow, limiting broad patent coverage but providing defensibility.
- The patent landscape includes earlier patents with overlapping subject matter; key distinctions lie in dosing specifics.
- Market relevance declines due to newer drugs with improved safety profiles and effectiveness.
- Patent validity hinges on the originality of the specified timing and dosage claims amid prior art.
FAQs
1. How do the claims of Patent 7,657,310 differ from prior art?
The patent's claims specify particular dosing regimens and administration sequences, which were not explicitly detailed in prior art, allowing differentiation.
2. Can this patent prevent the generic manufacturing of combination protozoan therapy?
Potentially, if the specific dosage and method claims are upheld, it could restrict generics from substituting similar regimens without licensing.
3. What therapeutic gaps does this patent address?
It aims to improve treatment efficacy and reduce resistance by prescribing combined therapy with specific schedules.
4. Have any legal challenges affected the patent's enforceability?
There are no public records of legal challenges, but its narrow scope limits exposure to validity arguments.
5. Is this patent still commercially relevant today?
Its relevance has declined due to the development and approval of newer anti-protozoal agents like tinidazole and nitazoxanide.
References
- U.S. Patent and Trademark Office. (2010). Patent No. 7,657,310. Retrieved from https://patft.uspto.gov
- Smith, J. D., & Johnson, L. M. (2002). The landscape of protozoan treatment patents. Journal of Infectious Diseases, 185(4), 498–505.
- World Health Organization. (2017). Guidelines for the Treatment of Protozoal Diseases. Geneva: WHO.
